44.42 USD
+0.41 (+0.93%)
Overall EXEL gets a fundamental rating of 8 out of 10. We evaluated EXEL against 534 industry peers in the Biotechnology industry. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties. EXEL is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make EXEL a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year EXEL was profitable.
EXEL had a positive operating cash flow in the past year.
In the past 5 years EXEL has always been profitable.
EXEL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of EXEL (24.01%) is better than 97.38% of its industry peers.
EXEL has a better Return On Equity (31.37%) than 97.57% of its industry peers.
Looking at the Return On Invested Capital, with a value of 26.31%, EXEL belongs to the top of the industry, outperforming 98.69% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for EXEL is significantly below the industry average of 18.60%.
The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(26.31%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROIC | 26.31% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
Looking at the Profit Margin, with a value of 29.63%, EXEL belongs to the top of the industry, outperforming 96.07% of the companies in the same industry.
EXEL's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 35.85%, EXEL belongs to the top of the industry, outperforming 97.57% of the companies in the same industry.
EXEL's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 96.63%, EXEL belongs to the top of the industry, outperforming 96.25% of the companies in the same industry.
EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
EXEL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, EXEL has less shares outstanding
Compared to 5 years ago, EXEL has less shares outstanding
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
EXEL has an Altman-Z score of 12.83. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 12.83, EXEL belongs to the top of the industry, outperforming 85.39% of the companies in the same industry.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.83 |
ROIC/WACC3.01
WACC8.73%
2.3 Liquidity
A Current Ratio of 3.75 indicates that EXEL has no problem at all paying its short term obligations.
EXEL's Current ratio of 3.75 is in line compared to the rest of the industry. EXEL outperforms 46.07% of its industry peers.
EXEL has a Quick Ratio of 3.68. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL's Quick ratio of 3.68 is in line compared to the rest of the industry. EXEL outperforms 47.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 |
3. Growth
3.1 Past
EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.51%, which is quite impressive.
Measured over the past years, EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.93%.
Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 17.51% on average per year.
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
3.2 Future
The Earnings Per Share is expected to grow by 25.76% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 9.99% on average over the next years. This is quite good.
EPS Next Y29.57%
EPS Next 2Y25.25%
EPS Next 3Y26.07%
EPS Next 5Y25.76%
Revenue Next Year7.2%
Revenue Next 2Y9.82%
Revenue Next 3Y11.52%
Revenue Next 5Y9.99%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 18.74, the valuation of EXEL can be described as rather expensive.
94.38% of the companies in the same industry are more expensive than EXEL, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.37. EXEL is valued slightly cheaper when compared to this.
EXEL is valuated correctly with a Price/Forward Earnings ratio of 15.31.
Based on the Price/Forward Earnings ratio, EXEL is valued cheaply inside the industry as 96.44% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of EXEL to the average of the S&P500 Index (36.20), we can say EXEL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.74 | ||
| Fwd PE | 15.31 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.07% of the companies listed in the same industry.
96.25% of the companies in the same industry are more expensive than EXEL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.27 | ||
| EV/EBITDA | 12 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
A more expensive valuation may be justified as EXEL's earnings are expected to grow with 26.07% in the coming years.
PEG (NY)0.63
PEG (5Y)1.48
EPS Next 2Y25.25%
EPS Next 3Y26.07%
5. Dividend
5.1 Amount
EXEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:EXEL (12/4/2025, 12:54:50 PM)
44.42
+0.41 (+0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.89%
Inst Owner Change-0.36%
Ins Owners2.23%
Ins Owner Change-3.14%
Market Cap11.91B
Revenue(TTM)2.29B
Net Income(TTM)677.90M
Analysts78.46
Price Target45.9 (3.33%)
Short Float %7.68%
Short Ratio7.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.63%
Min EPS beat(2)9.27%
Max EPS beat(2)13.99%
EPS beat(4)4
Avg EPS beat(4)20.73%
Min EPS beat(4)9.27%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)31.52%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)13
Avg EPS beat(16)41.2%
Revenue beat(2)0
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.36%
Revenue beat(12)4
Avg Revenue beat(12)2.52%
Revenue beat(16)7
Avg Revenue beat(16)3.42%
PT rev (1m)1.54%
PT rev (3m)0%
EPS NQ rev (1m)16.08%
EPS NQ rev (3m)20.6%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)1.42%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)-0.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.74 | ||
| Fwd PE | 15.31 | ||
| P/S | 5.2 | ||
| P/FCF | 15.27 | ||
| P/OCF | 15.06 | ||
| P/B | 5.51 | ||
| P/tB | 5.68 | ||
| EV/EBITDA | 12 |
EPS(TTM)2.37
EY5.34%
EPS(NY)2.9
Fwd EY6.53%
FCF(TTM)2.91
FCFY6.55%
OCF(TTM)2.95
OCFY6.64%
SpS8.53
BVpS8.06
TBVpS7.82
PEG (NY)0.63
PEG (5Y)1.48
Graham Number20.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROCE | 33.48% | ||
| ROIC | 26.31% | ||
| ROICexc | 44.11% | ||
| ROICexgc | 46.12% | ||
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% | ||
| FCFM | 34.08% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 37.81% | ||
| Cap/Sales | 0.49% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 93.06% | ||
| Profit Quality | 115.03% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 | ||
| Altman-Z | 12.83 |
F-Score8
WACC8.73%
ROIC/WACC3.01
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
EPS Next Y29.57%
EPS Next 2Y25.25%
EPS Next 3Y26.07%
EPS Next 5Y25.76%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
Revenue Next Year7.2%
Revenue Next 2Y9.82%
Revenue Next 3Y11.52%
Revenue Next 5Y9.99%
EBIT growth 1Y34.85%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year41.83%
EBIT Next 3Y24.19%
EBIT Next 5Y1.16%
FCF growth 1Y112.18%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y99.5%
OCF growth 3Y20.43%
OCF growth 5Y5.84%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
What is the valuation status for EXEL stock?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
What is the profitability of EXEL stock?
EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.
What are the PE and PB ratios of EXELIXIS INC (EXEL) stock?
The Price/Earnings (PE) ratio for EXELIXIS INC (EXEL) is 18.74 and the Price/Book (PB) ratio is 5.51.